Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

ore than six months.

To date, five dose-limiting toxicities (DLTs) have been reported, including Grade 3 palmar/plantar erythema (hand-foot syndrome), Grade 3 AST elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients dosed at 11.52 mg/kg (intermittent dosing schedule), as well as a DLT of Grade 2 mucositis in a patient dosed at 265 mg (daily dosing schedule). Serious adverse events (AEs) considered possibly or probably related to XL184 include one report each of Grade 3 fatigue and Grade 3 pulmonary embolism. Dose escalation continues in order to determine a maximum tolerated dose (MTD).

About XL184

XL184 is a novel, orally administered, small molecule anticancer compound that in preclinical models has demonstrated potent inhibition of both MET and VEGFR2. XL184 has also exhibited potent inhibition of other important receptor tyrosine kinases (RTKs) that have been implicated in various forms of cancer including RET, KIT, FLT3, and TIE2. In preclinical efficacy studies, XL184 has inhibited tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breast cancer, lung cancer and glioma. In laboratory studies, XL184 has demonstrated good oral bioavailability and pharmacokinetic properties.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Com
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Inc. (NYSE: RMD ) today announced results for ... quarter was $422.5 million, a 6 percent increase compared ... percent increase on a constant currency basis).  Net income ... to the quarter ended March 31, 2014.  Diluted earnings ... of 2 percent compared to the quarter ended March ...
(Date:4/23/2015)... 23, 2015  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... first quarter financial results on Thursday, May 7, 2015, ... will host a live audio webcast immediately following the ... first quarter 2015 financial results and provide a business ... the live audio webcast via the Investors & Media ...
(Date:4/23/2015)... 2015 Surna, Inc. (OTCQB: SRNA), a technology ... equipment and systems for controlled environment agriculture ("CEA") ... will host a shareholder conference call to discuss ... 4:15 PM Eastern Standard Time/1:15 PM Pacific Standard ... be listen-in only, but will include a Q&A ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
... online marketplace for medical equipment , is pleased ... a comparison feature that allows buyers to select as ... them in making the best buying decision. Once the ... chart is automatically generated, making it simple to view ...
... N.J., Sept. 1 QRxPharma (ASX: QRX and OTCQX: ... final MoxDuo IR pivotal Phase 3 study required for ... planned sample size of 140 patients has greater than ... there is no need to enrol additional patients. QRxPharma ...
Cached Medicine Technology:MedWOW Adds Comparison Tool for Shoppers' Medical Equipment - Offers eBook Free to New Registrants 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 3
(Date:4/25/2015)... 25, 2015 In the United States ... above needed treatment for an illicit drug ... Abuse and Mental Health Services Administration’s Survey on Drug ... alarming numbers are harrowing stories of men and women ... . David H. Kerr , founder and retired ...
(Date:4/25/2015)... NV (PRWEB) April 25, 2015 The ... is still eliciting the excitement of the public and ... into the months of May and June. From ... held their biannual tradition of "Special Prayers." More than ... had attended previous Special Prayers and have reported intense ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... Bird B Gone, the leader in bird control products ... line of bird control solutions to address the growing threat ... Threaten Pacific, Central and Mississippi Farms , According to an ... of highly pathogenic avian flus in the Pacific, Central and ... wild birds enter poultry farms. The USDA urges farmers to ...
(Date:4/24/2015)... 2015 Ryadon is a leading manufacturer ... capabilities and services to complement any custom hardware requirements ... Program will be offered on all heavy duty drawer ... Receive 10% discount - Order 20+: Receive 20% discount ... Slides Products, Furniture ,Drawer ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... disease through causing inflammation of the arteries. There is mounting evidence ... new study uncovers a link between the mouth and the heart ... Buffalo find that people with gum disease have higher than normal ... enter the circulation via the gums, and then trigger the liver ...
... way of treating tissue at the back of the mouth is ... 30 per cent of women have a problem with snoring - ... in the soft palate - the area of tissue at the ... tonsils, and the base of the tongue. Surgery that makes this ...
... disease also improves the paralysis experienced by stroke survivors.,Levodopa ... and this may help brain cells involved in controlling ... treatment in Parkinson's disease, but a new trial suggests ... ,// ,Researchers at the Bad Aibling Neurological ...
... Researchers at the University of Pittsburgh School of Medicine ... women's concerns about weight is the first treatment to ... for weight-concerned women assumed that the best approach to ... weight gain after they quit smoking. This study, as ...
... influence the risk of oesophagal cancer. ,A family in Liverpool, ... the genetic basis of cancer of the oesophagus. Twenty one ... five generations. The disease affects those who also have a ... researchers are studying 350 members of the extended Liverpool family. ...
... who eat the healthiest diets also eat a lot of ... Index (HEI) is a measure that US nutritionists have developed ... eating pattern rather than intake of specific nutrients. You get ... milk or meat, ten more possible points for dietary limitations ...
Cached Medicine News:Health News:Stop smoking and reduce weight 2
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: